Addex Therapeutics Ltd (NAS:ADXN)
$ 8.71 0.0859 (1%) Market Cap: 9.32 Mil Enterprise Value: 5.56 Mil PE Ratio: 9,999.00 PB Ratio: 0.72 GF Score: 56/100

Q3 2024 Addex Therapeutics Ltd Earnings Call Transcript

Nov 22, 2024 / 03:00PM GMT
Release Date Price: $10.78 (+2.18%)
Tim Dyer
Addex Therapeutics Ltd - Chief Executive Officer, Co-Founder, Member of the Executive Management, Director

Hello, everyone. I would like to thank you all for attending our third quarter 2024 financial results conference call. I'm here with Mikhail Kalinichev, our Head of Translational Science who will provide an update on our R&D programs. I draw your attention to the press release and the financial statements issued earlier today, which are available on our website.

I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha who will review in more detail our GABAB PAM preclinical program. I will then review our third-quarter 2024 financial results. Following that, we will open the call for questions.

So we have made excellent progress in our GABAB positive allosteric modulator program with the completion of the R&D

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot